|
|
|
|
|
Terbutaline
drug data and news
Terbutaline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Terbutaline | ||
| Brand Names/Synonyms | Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; CHEMBANK743; KWD 2019; T2528; Terbutalin; Terbutalina [Dcit]; Terbutaline; Terbutaline Sulfate; Terbutalino [Inn-Spanish]; Terbutalinum [Inn-Latin] | ||
| Indication | For the prevention of and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema; For the management of preterm labor | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Terbutaline is a relatively selective beta2-adrenergic bronchodilator. Terbutaline is indicated for the relief of bronchospasm associated with chronic obstructive pulmonary disease. The pharmacologic effects of beta adrenergic agonist drugs, including Terbutaline, are at least in part attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. | ||
| Mechanism Of Action | The pharmacologic effects of Terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. | ||
| Terbutaline News (When available) |
| ||
| Dosage Forms | METERED-DOSE (AEROSOL); POWDER; Tablets; IV Injection; Subcutaneous Injection | ||
| Drug_Category | Adrenergic beta-Agonists; Tocolytic Agents; Bronchodilator Agents; Sympathomimetic; ATC:R03AC03; ATC:R03CC03 | ||
| Absorption | Not Available | ||
| Interactions | Drug Interactions: The concomitant use of Terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline on the vascular system may be potentiated. Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Terbutaline, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics. | ||
| Toxicity | Terbutaline Sulfate: Oral LD50(rat) = 8.7 g/kg; Oral LD50(mouse) = 205 mg/kg; Oral LD50(dog) = 1.5 g/kg; IP LD50(rat)= 220 mg/kg ; IP LD50(mouse) = 130 mg/kg; Oral LD50(rabbit) = >8 g/kg; IV LD50(mouse) = 36 mg/kg; IV LD50(dog) = 116 mg/kg; IV LD50(rabbit) = 110 mg/kg | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-(1-hydroxy-2-tert-butylamino-ethyl)benzene-1,3-diol | ||
| Chemical Formula | C12H19NO3 | ||
| Molecular Weight | 225.284 g/mol | ||
| Smiles String | CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O | ||
| Melting Point | 119-122 °C | ||
| Water Solubility | 213 mg/ml | ||
| State | Solid | ||
| LogP/Hphobicity | 1.567 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 5.5-5.9 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Terbutaline.html http://www.rxlist.com/cgi/generic3/terbutaline.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00589 | ||
| CAS Registry Number | 23031-25-6 | ||
| KEGG Compound ID | C07129 | ||
| PubChem ID | SID:9339 | ||
| PharmGKB ID | PA451616 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 786616 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |